Abstract
s / Biol Blood Marrow Transplant 19 (2013) S313eS341 S314 lines: Raji-2R and Raji-4RH (P< .001). However, there was no significant difference against CD20control cells: RS4;11 and Jurkat. Consistently, intracellular CD107a degranulation was enhanced in CAR+ exPBNK compared to CARexPBNK in response to CD20+ Ramos. MIC expressionwas significantly increased in Ramos (P< .05) and in NALM-6 (P < .001) after romidepsin treatment. CD20 expression was significantly increased in NALM-6 (P < .001) after romidepsin treatment. CAR+ exPBNK in vitro cytotoxicity was significantly enhanced against romidepsin treated Ramos (P< .02) and NALM-6 (P< .01) compared to untreated targets. Conclusion: Anti-CD20 CAR expression in exPBNK cells results in significant and specific in vitro cytotoxicity against CD20+ B-L/L. Romidepsin increases MICA/B and CD20 expression in B-L/L. CAR exPBNK significantly enhanced cytotoxicity against romidepsin treated B-L/L. Future directions include examining the combination effect of CAR exPBNK and Romidepsin against B-L/L in xenograft mice.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
